This site and its domain are for sale. Email the owner if you want to talk about it.

compoundglp.com

Compounded GLP-1s With Added B12 or Glycine: Medicine or Marketing?

A vitamin in the vial may do little for the patient, and quite a lot for the paperwork.

A small glass vial and a syringe resting on a pharmacy counter beside a tray of unlabeled capsules, soft natural light.

I spent an evening this week reading a 2025 survey of compounded weight-loss injections, and the finding I keep coming back to is that about half of them are not only weight-loss injections. They have other stuff in them. The survey lists cyanocobalamin (vitamin B12), glycine, niacinamide, docusate and ondansetron, mixed in with the semaglutide or tirzepatide in the same product.

If you searched for semaglutide with b12, here is the plain answer. It is compounded semaglutide with cyanocobalamin added, made by a compounding pharmacy rather than by a drug manufacturer, and it is not an FDA-approved product. The survey that counted these combinations was published under the title “Compounded Semaglutide and Tirzepatide Products Use Unique Formulations but Efficacy and Safety Largely Unknown,” and that title is about as far as the evidence goes. Nothing in the facts I have shows that the B12 makes the semaglutide work better or more safely. It is not settled. It is barely studied.

What semaglutide with B12 actually is

A compounded drug is one a pharmacy mixes itself instead of buying it finished from a manufacturer. (The site has longer pieces on what compounders are and on the two kinds the law allows, so I will not redo them here.) Compounded semaglutide is semaglutide made this way. Compounded semaglutide with B12 is that, plus a vitamin.

The marketing word for these products tends to be “personalized,” which suggests a pharmacist looking at one particular patient and deciding that patient needs a little extra something. That is one possible description. The survey suggests another, which is that this is a catalog. There were 33 unique semaglutide and tirzepatide products in it, and the combinations recur across them. A personalized product that many people receive in the same form is sort of a product.

Why the law makes adding a vitamin interesting

Here is the rule. Compounders entered the GLP-1 market in 2022, when demand for semaglutide and tirzepatide outstripped supply and both drugs were placed on the FDA Drug Shortage List. That mattered because, as one source summarizing the law puts it, “Compounding a copy of an FDA-approved drug is ordinarily prohibited,” but the shortage exception in sections 503A and 503B allowed it while the drugs were on the list.

So the legal question is not really “is this drug good.” It is “is this a copy.” During a shortage, copies are fine. Without a shortage, copies are the problem.

The facts I have do not spell out what follows from that, so I will, labeled as my own inference: if the forbidden thing is a copy, then a thing that is not a copy might not be forbidden. The approved product is semaglutide. A vial of semaglutide plus a vitamin is, read very literally, a different preparation. Whether that literal reading actually holds up with regulators is not something these sources settle, and I would not pretend otherwise.

But you can see how the conversation might go. (This is invented.) A compliance consultant, on a call with a pharmacy, says: “Hey guys, it’s not a copy if it’s personalized. What are we personalizing it with?” Someone suggests B12. Everyone likes B12 (it has never once been the villain of a press release). B12 sounds healthy.

And then, in my invented version, it keeps going. If B12 makes it different, B12 plus glycine makes it more different. Add niacinamide for safety margin. Add docusate. Eventually the pharmacy is compounding a single vial containing a weight-loss drug, four supporting cast members, and a mild sense of legal distance, and the one thing it is definitely not is a copy of anything that has ever existed. This is made up. Mostly.

What the evidence says about the additives

The survey is the main evidence, and it is a count, not a trial. It does not test whether B12 does anything in these products. It just notices the B12 is there.

The number I cannot stop looking at is the 48%. That is the share of the 33 products that contained drug combinations. But 48% of 33 is 15.84 products, and you cannot have 0.84 of a product. Presumably the real figure is 16, which is 48.48% and rounds down nicely. I find this weirdly moving: someone sat with a spreadsheet of vitamin-laced weight-loss vials and did the honest arithmetic, and the rounding quietly hides a whole product. (I am aware that dwelling on the decimal places of a survey is not a normal way to spend an evening. It is, unfortunately, my job.)

The other number is worse. Only 18% of the products provided beyond-use-date information, meaning how long the preparation is good for once made. So the additives were often listed, and the expiration often was not. Priorities.

For safety, the broadest data comes from a study of the FDA Adverse Event Reporting System, by McCall and colleagues, covering 81,078 GLP-1 reports from 2018 to 2024, of which 707 involved compounded products. Compared with non-compounded versions, compounded products had a reporting odds ratio of 48.92 for preparation errors, 19.00 for contamination and 2.35 for hospitalization. Those confidence intervals are wide (the preparation-error one runs from 12.63 to 189.6), and these are reports, not proof of cause. Crucially for this article, the study looked at compounded GLP-1s as a group. It does not tell us whether the B12 versions were better, worse or the same. Nobody in these sources has measured that.

One oddity, briefly: compounded products showed lower odds of dosing errors, with an ROR of 0.24. The site’s piece on dosing errors handles that tangle, so I will leave it there.

What happened after the shortage ended

The semaglutide shortage ended in February 2025. Some compounders and direct-to-consumer platforms kept making compounded GLP-1s anyway, which led to scrutiny and legal action. In September 2025 the FDA sent warning letters citing misleading direct-to-consumer advertising and marketing of compounded GLP-1s.

Novo Nordisk, which makes the branded semaglutide, went to court in volume. As of August 5, 2025, it had filed 132 complaints in federal courts across 40 states, describing the targets in a press release about “unsafe, non-FDA-approved compounded ‘semaglutide.’” (Note the scare quotes around the drug’s own name, which is a fairly pointed thing for a company to do to its own molecule.) That same day it filed 14 new suits against telehealth providers for allegedly steering patients toward compounded semaglutide. The lawsuits get their own article on this site.

The point for our purposes is timing. Once the shortage was over, the plain copy lost its legal cover. Whatever the additives were doing before, they mattered more after.

Three ways to read the B12

There are, roughly, three ways to read a weight-loss injection that comes with a vitamin.

The first is that it is medicine. A pharmacist thinks some patients benefit from extra B12, and combining it saves a second shot. This is the reading the word “personalized” asks you to adopt, and it might be true for some prescribers. The trouble is just that the evidence for the combination, in the sources here, is close to zero. The survey’s own title says efficacy and safety are “largely unknown.”

The second is that it is marketing. Look, B12 sounds wholesome. A landing page offering a weight-loss shot “with B12” reads like a wellness product rather than a prescription drug made in a back room. The FDA’s September 2025 letters were specifically about misleading marketing of compounded GLP-1s, though the facts I have do not say any of them were about B12 in particular. It must simply be a happy coincidence that the ingredient chosen for its clinical value also photographs so well.

The third reading is the least comfortable one, and I feel like it is the one the law invites. The additive is not there for the patient, or for the advertisement. It is there for the statute. If copies are ordinarily prohibited, then the most useful property of B12 is that it makes the product not a copy, and “personalized” describes the vial’s relationship to section 503A rather than its relationship to anybody’s body. Then again, those readings can coexist: a pharmacist might sincerely believe in the B12 and also appreciate what it does for the paperwork, and from the outside I do not know how you would tell one motive from the other. The sources do not tell us either.

Which brings me back to that survey I read this week, and the half of the vials that had other things in them. I started out thinking the vitamins were the odd part. Now the vitamins seem like the most purposeful thing in the whole vial.

The vitamin is for the law.

Sources

  1. Compounded Semaglutide and Tirzepatide Products Use Unique Formulations but Efficacy and Safety Largely Unknown
  2. How GLP-1s Broke Healthcare Distribution | Contrary Research
  3. FDA and Novo Nordisk Warned of GLP-1 Telehealth Compounding Takedown. What’s Next? | Pharmacy Times
  4. Novo Nordisk expands legal action to protect US patients from unsafe, non-FDA-approved compounded "semaglutide"
  5. Safety analysis of compounded GLP-1 receptor agonists: a pharmacovigilance study using the FDA adverse event reporting system
  6. Safety analysis of compounded GLP-1 receptor agonists: a pharmacovigilance study using the FDA adverse event reporting system
  7. Semaglutide Compounding Pharmacy: What's Legal In 2026
  8. The Shot Heard ‘Round the Pharmacy’: FDA Takes Aim at GLP-1 Compounders | ArentFox Schiff
  9. Semaglutide Salt Forms: Why the Base Matters
  10. Compounded GLP-1s: Why doctors worry and the FDA is cracking down

Compound GLP explains the law and published research. It is not medical or legal advice, and it never recommends a dose, a pharmacy or a product. Talk to a clinician before you start, stop or change any medicine.

Read next